A cancer vaccine is closer than ever

Scientists may be on the verge of a long-awaited breakthrough: utilizing vaccines to train the immune system to identify and eliminate cancer cells. The application of an mRNA cancer vaccine, developed by Merck & Co. and Moderna Inc., has shown promise in a large, late-stage trial, effectively preventing melanoma from recurring. This marks a significant milestone for a technology that has faced numerous setbacks over the years, including political opposition following the pandemic and repeated false starts.

For over a century, the idea of cancer vaccines has captured the interest of researchers, with headlines promising potential treatments in the past two decades. However, none of these efforts have ultimately proven successful. Coaxing the body to combat its own cells has proven to be an exceedingly challenging task. The recent advancements in mRNA technology are now enabling researchers to move beyond the initial "hope" and "promise" phase.

Merck & Moderna's Phase 3 study, involving the personalized mRNA-based vaccine intismeran alongside the immunotherapy Keytruda, provides compelling evidence that cancer vaccines can indeed be effective. Although further research is needed to demonstrate their potential applicability to various types of cancer, this development brings us one step closer to a groundbreaking treatment.